🇺🇸 FDA
Pipeline program

lymphocyte gene therapy

199/13577

Phase 2 gene_therapy completed

Quick answer

lymphocyte gene therapy for Mucopolysaccharidosis II is a Phase 2 program (gene_therapy) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Mucopolysaccharidosis II
Phase
Phase 2
Modality
gene_therapy
Status
completed

Clinical trials